Cargando…

Reply to Chacko et al.: Limited Assessment of Respiratory Muscle Response to Nusinersen Treatment in Infants with Spinal Muscular Atrophy

Detalles Bibliográficos
Autores principales:	LoMauro, Antonella, Mastella, Chiara, Alberti, Katia, Masson, Riccardo, Aliverti, Andrea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Thoracic Society 2020
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7047463/ https://www.ncbi.nlm.nih.gov/pubmed/31747301 http://dx.doi.org/10.1164/rccm.201910-2022LE

Ejemplares similares

A New Method for Measuring Bell-Shaped Chest Induced by Impaired Ribcage Muscles in Spinal Muscular Atrophy Children
por: LoMauro, Antonella, et al.
Publicado: (2018)

Spontaneous Breathing Pattern as Respiratory Functional Outcome in Children with Spinal Muscular Atrophy (SMA)
por: LoMauro, A., et al.
Publicado: (2016)

Nusinersen for spinal muscular atrophy
por: Wurster, Claudia D., et al.
Publicado: (2018)

Intellectual abilities, language comprehension, speech, and motor function in children with spinal muscular atrophy type 1
por: Zappa, Grazia, et al.
Publicado: (2021)

Limited Assessment of Respiratory Muscle Response to Nusinersen Treatment in Infants with Spinal Muscular Atrophy
por: Chacko, Archana, et al.
Publicado: (2020)

Nusinersen Treatment in Adults With Spinal Muscular Atrophy
por: Duong, Tina, et al.
Publicado: (2021)

Assessment and management of respiratory function in patients with Duchenne muscular dystrophy: current and emerging options
por: LoMauro, Antonella, et al.
Publicado: (2015)

Nusinersen as a Therapeutic Agent for Spinal Muscular Atrophy
por: Li, Qing
Publicado: (2020)

Nusinersen and Spinal Muscular Atrophies: Where are we in 2020?
por: Khadilkar, Satish V., et al.
Publicado: (2020)

Legends of Indian Orthopedics: Dr. Verghese Chacko
por: Kishen, Thomas, et al.
Publicado: (2018)

Nusinersen in pediatric and adult patients with type III spinal muscular atrophy
por: Pera, Maria Carmela, et al.
Publicado: (2021)

Fatigue in adults with spinal muscular atrophy under treatment with nusinersen
por: Kizina, K., et al.
Publicado: (2020)

Parents’ perspectives on nusinersen treatment for children with spinal muscular atrophy
por: van Kruijsbergen, Mette, et al.
Publicado: (2021)

Safety and efficacy of nusinersen in spinal muscular atrophy: The EMBRACE study
por: Acsadi, Gyula, et al.
Publicado: (2021)

Nusinersen: A Review in 5q Spinal Muscular Atrophy
por: Hoy, Sheridan M.
Publicado: (2021)

Scoliosis in Spinal Muscular Atrophy Type 1 in the Nusinersen Era
por: Al Amrani, Fatima, et al.
Publicado: (2022)

Nusinersen mitigates neuroinflammation in severe spinal muscular atrophy patients
por: Nuzzo, Tommaso, et al.
Publicado: (2023)

Non-Invasive Respiratory Assessment in Duchenne Muscular Dystrophy: From Clinical Research to Outcome Measures
por: Pennati, Francesca, et al.
Publicado: (2021)

Nusinersen in type 0 spinal muscular atrophy: should we treat?
por: Tiberi, Eloisa, et al.
Publicado: (2020)

Correction to: Nusinersen: A Review in 5q Spinal Muscular Atrophy
por: Hoy, Sheridan M.
Publicado: (2021)

History of development of the life-saving drug “Nusinersen” in spinal muscular atrophy
por: Qiu, Jiaying, et al.
Publicado: (2022)

Respiratory physiology of pregnancy: Physiology masterclass
por: LoMauro, Antonella, et al.
Publicado: (2015)

Physiology masterclass: Extremes of age: newborn and infancy
por: LoMauro, Antonella, et al.
Publicado: (2016)

Blood Shift During Cough: Negligible or Significant?
por: LoMauro, Antonella, et al.
Publicado: (2018)

Sex differences in respiratory function
por: LoMauro, Antonella, et al.
Publicado: (2018)

Sex and gender in respiratory physiology
por: LoMauro, Antonella, et al.
Publicado: (2021)

Nusinersen efficacy data for 24‐month in type 2 and 3 spinal muscular atrophy
por: Pane, Marika, et al.
Publicado: (2022)

Intrathecal Injections in Children With Spinal Muscular Atrophy: Nusinersen Clinical Trial Experience
por: Haché, Manon, et al.
Publicado: (2016)

Feasibility and safety of intrathecal treatment with nusinersen in adult patients with spinal muscular atrophy
por: Stolte, Benjamin, et al.
Publicado: (2018)

Cost effectiveness of nusinersen for patients with infantile-onset spinal muscular atrophy in US
por: Thokala, Praveen, et al.
Publicado: (2020)

Nusinersen Wearing-Off in Adult 5q-Spinal Muscular Atrophy Patients
por: Osmanovic, Alma, et al.
Publicado: (2021)

Treatment satisfaction in 5q-spinal muscular atrophy under nusinersen therapy
por: Osmanovic, Alma, et al.
Publicado: (2021)

Increased chitotriosidase 1 concentration following nusinersen treatment in spinal muscular atrophy
por: Freigang, Maren, et al.
Publicado: (2021)

Safety, Tolerability, and Effect of Nusinersen in Non-ambulatory Adults With Spinal Muscular Atrophy
por: Elsheikh, Bakri, et al.
Publicado: (2021)

Motor unit changes in children with symptomatic spinal muscular atrophy treated with nusinersen
por: Kariyawasam, Didu, et al.
Publicado: (2021)

Nusinersen Induces Disease-Severity-Specific Neurometabolic Effects in Spinal Muscular Atrophy
por: Errico, Francesco, et al.
Publicado: (2022)

Evolution of bulbar function in spinal muscular atrophy type 1 treated with nusinersen
por: Weststrate, Harriet, et al.
Publicado: (2022)

Cerebrospinal fluid characteristics of patients treated with intrathecal nusinersen for spinal muscular atrophy
por: Orbach, Rotem, et al.
Publicado: (2022)

Cerebrospinal Fluid Proteomic Changes after Nusinersen in Patients with Spinal Muscular Atrophy
por: Beaudin, Marie, et al.
Publicado: (2023)

Thoracoabdominal Asynchrony Contributes to Exercise Limitation in Mild Asthmatic Subjects
por: Fregonezi, Guilherme, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_4rl5f6p43vsv80ocofdhqvlff8